FimmCyte and Richter Collaborate on Endometriosis Breakthrough – Startupticker.ch
Startupticker.ch shared a post on LinkedIn։
“FimmCyte, a femtech company developing new treatments for endometriosis, has entered into a research collaboration and option-to-license agreement with Richter, a leading Hungarian pharmaceutical company, to advance research on its lead clinical candidate, FMC2. The parties have fully negotiated a definitive, exclusive and worldwide license agreement for the future development and commercialization of the antibody. FimmCyte will be eligible to receive development and commercial milestone payments, together with tiered royalties on net sales, as provided under the pre-agreed license agreement.
More about FimmCyte, its clinical candidate and the collaboration in our article․”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Sep 13, 2026, 15:11Sachintha Alwis: From Impaired Sperm Motility to Microrobotics
-
Sep 13, 2026, 15:08Laurence Orbuch: Before Endometriosis Surgery, Ask…
-
Sep 13, 2026, 15:05Ademola Ayodele: IUI, IVF or Egg Freezing – Which One Is Right for You?
-
Sep 13, 2026, 14:59Fiona Pathiraja-Møller: Tennis Players No Longer Have to Choose Between Career and Family
-
Sep 13, 2026, 14:571-Day Virtual Experience for People Impacted by PMOS – PCOS Awareness Association
-
Sep 13, 2026, 14:53Ozor Victor: Behind Every Embryo Is a Story of Science, Precision, and Hope
-
Sep 13, 2026, 14:50Diana Kayal: What They Don’t Tell You About IVF
-
Sep 13, 2026, 14:44Vikram Sinai Talaulikar: A Heartfelt Thank You to All Who Donated and Supported “Menopause and Cancer”
-
Sep 13, 2026, 14:41Nicole McPherson: Changing IVF Practices Is Hard – Integration Needs to Be Easy